Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study
一项前瞻性、单臂、II期研究:以5.5 GBq/周期剂量使用177Lu-PSMA-617放射性配体治疗晚期去势抵抗性前列腺癌患者的疗效、毒性和临床结果。
期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-025-07661-w
Marini, Irene; Giunta, Emilio Francesco; Nicolini, Silvia; Grassi, Ilaria; Foca, Flavia; Sarnelli, Anna; Di Iorio, Valentina; Vizza, Lilla; Giani, Erika; Celli, Monica; Monti, Manuela; Severi, Stefano; De Giorgi, Ugo; Borgia, Francesca; Paganelli, Giovanni; Matteucci, Federica; Sansovini, Maddalena